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This article considers evidence for the efficacy and safety of bronchial thermoplasty from 
clinical trials and observational studies in clinical practice. Its place in the management of 




Bronchial thermoplasty improves quality of life and reduces exacerbations in moderate to 
severe asthma. Morbidity from asthma is increased during treatment. Overall, patients treated 
in clinical practice have worse baseline characteristics and comparable clinical outcomes to trial 
data. Follow-up studies provide reassurance on long-term safety. Despite some progress, future 
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research needs to investigate uncertainties about predictors of response, mechanism of action 
and place in management of asthma. 
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Asthma is a chronic inflammatory disease of the airways that affects 300 million people 
worldwide. Most adults with asthma have mild or moderate disease that potentially can be 
controlled by inhaled corticosteroids (ICS) alone or in combination with an inhaled long-acting 
ß2 agonist (LABA) bronchodilator [1]. Despite the use of current therapies, surveys indicate that 
many patients have poorly controlled symptoms and experience frequent exacerbations [2,3] 
due to a range of aggravating factors, such as non-adherence, poor inhaler technique, co-
morbidities, under treatment and patient characteristics. After identifying and treating 
contributing factors, a sub-group of patients with difficult-to-control asthma have severe 
symptomatic disease despite treatment with high-dose ICS and LABA in combination or with 
continuous or frequent oral corticosteroids [4-7]. The prevalence of difficult-to-control asthma 
is estimated to be 17.4% of the total asthmatic population, of whom approximately one fifth 
have severe refractory disease [8]. Patients with severe asthma have reduced life-expectancy 
and experience substantial morbidity due to poorly controlled asthma and the adverse effects 
of high-dose corticosteroids [9]. The financial costs of severe asthma are high due to 
medications, hospital admissions and time lost from work [10]. Severe asthma persists in most 
patients, particularly in those with low socioeconomic status and greater comorbidities [11].  
 
Recognition of the heterogeneity of clinical and inflammatory phenotypes of severe asthma has 
encouraged the development of new treatments, such as monoclonal antibodies targeting 
immunoglobulin E (anti-IgE) and persistent eosinophilic and type 2 inflammation [12,13]. Anti-
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IgE therapy with omalizumab is a treatment option for severe allergic asthma. Humanized 
monoclonal antibodies against human interleukin (IL)-5, such as mepolizumab and reslizumab 
and against the IL-5 receptor α, such as benralizumab, were recently approved for add-on 
maintenance treatment in patients aged 18 years or older with severe eosinophilic asthma. 
Other therapies targeting type 2 inflammation are in development [13]. Despite this progress, 
there is a limited understanding of other potentially important phenotypes and endotypes of 
severe asthma, such as non-eosinophilic asthma and non-type 2 inflammation and there is a 
bottleneck in the development of novel treatments for certain subtypes of severe asthma [14].  
 
Bronchial thermoplasty is an intervention developed for the treatment of patients with 
moderate and severe asthma, which involves the delivery of radio frequency energy to the 
airways [15]. Bronchial thermoplasty is licensed for the treatment of asthma in the United 
States, Europe, China and in many other countries. The Food & Drug Administration (FDA) gave 
premarket approval (PMA) for the Alair bronchial thermoplasty system as a treatment of 
severe persistent asthma in patients 18 years and older whose asthma is not well controlled 
with ICS and LABA in 2010 [16]. In the European Union, the ‘Alair’ bronchial thermoplasty 
system has a CE Mark for the treatment of asthma in patients 18 years and older. Controversy 
exists on the strength of the evidence for the efficacy and safety of bronchial thermoplasty in 
severe asthma. There are also uncertainties about the effectiveness and safety of bronchial 
thermoplasty in clinical practice, whether it is possible to predict which patients will obtain 
clinical benefit from the procedure and its mechanism of action. This review summarizes the 
pre-clinical and clinical development of bronchial thermoplasty and considers its place in 
6 
 
management of severe asthma in clinical practice. Recent publications on the potential 
predictors of response and mechanisms of action are discussed. 
 
2. Development of bronchial thermoplasty 
 
Bronchial thermoplasty was developed as a procedure to reduce the amount of airway smooth 
muscle in severe asthma through the local application of thermal energy to the airways  with 
the aim of improving asthma control [15]. Previously published articles provide detailed reviews 
of the preclinical and clinical development of bronchial thermoplasty [15,17-21]. The key 
components of the development program are summarized in the following sections. 
 
Preclinical and early clinical studies 
 
Preclinical studies in dogs demonstrated that bronchial thermoplasty treatment of conducting 
airways > 3 mm in diameter, controlled to a temperature of 650C, decreased airway 
responsiveness to methacholine and reduced airway smooth muscle mass up to three years 
after the procedure [22]. The change in airway responsiveness to methacholine was inversely 
correlated to the extent of the reduction in airway smooth muscle [22]. Further canine studies 
showed that bronchial thermoplasty increased airway luminal area, as assessed by changes in 
computed tomography [23] and in lung inflation pressures [24]. The first study in humans found 
that bronchial thermoplasty could be safely performed in patients with bronchial carcinoma 
awaiting lung resection and resulted in reductions of airway smooth muscle mass [25]. In an 
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observational study of patients with mild to moderate asthma, bronchial thermoplasty was well 
tolerated and decreased airway responsiveness to methacholine for at least two years [26]. 
Based on the findings that bronchial thermoplasty was associated with reductions in airway 
smooth muscle in dogs and man and that the procedure could be safely performed in patients 
with asthma, controlled clinical trials of bronchial thermoplasty were initiated in patients with 
moderate and severe asthma. 
 
Equipment and procedure 
 
The ‘Alair’ Bronchial Thermoplasty system includes a radiofrequency generator that regulates 
the energy applied to the airways and a catheter with an expandable electrode array at its 
distal end, which is connected to the controller via an integral electrical cable. A footswitch 
triggers a 10 second period of radiofrequency energy delivered via the catheter. The treatment 
involves three bronchoscopy sessions with repeated activations of a radiofrequency catheter 
within the medium and large airways [27,28]. Bronchial thermoplasty is performed by 
pulmonary physicians with experience in bronchoscopy and at facilities equipped to handle 
respiratory emergencies. Bronchoscopists must undergo special training before undertaking 
their first procedure as stipulated by the manufactures of the ‘Alair’ system. Patients receive 
prophylactic prednisolone or equivalent at a dose of 50 mg per day for the three days before 
the procedure, the day of the procedure and the day after the procedure.  Pre-procedure FEV1 
should be greater than or equal to 85% of a patient’s recent value when stable. Patients receive 
treatment over three outpatient flexible bronchoscopy sessions under conscious sedation 
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spaced at approximately three-week intervals, one for each lower lobe and one for both upper 
lobes. In some centers, bronchial thermoplasty is performed under general anesthesia. 
Different sedation regimes are used, including mild sedation with midazolam and alfentanil, 
moderate sedation with target-controlled infusion of propofol and remifentanil or general 
anesthesia [27,29]. The bronchoscope is placed in the distal aspect of the airway being treated 
and the ‘Alair’ catheter is advanced under visual guidance. The treatment involves repeated, 
precise and carefully recorded activations of a radiofrequency catheter within the medium and 
large airways. A treatment session is typically completed in 45 minutes and around 60 
radiofrequency energy treatments delivered to the airways. Before each subsequent session 
the airways treated in the previous procedure are inspected for persisting inflammation or 
infection. After each procedure patients are carefully monitored and discharged only when the 
post-bronchodilator FEV1 is within 80% of the pre-procedure value and the patient’s medical 
condition is considered stable. The feasibility of hyperpolarized xenon (HXe) magnetic 
resonance imaging (MRI) as a biomarker to prioritize the order of airway treatment by 
bronchial thermoplasty is being assessed in patients with severe asthma (ClinicalTrials.gov 
Identifier: NCT01832363; NCT02263794) [30].  
 
Controlled clinical trials of bronchial thermoplasty 
 
Evidence for the efficacy and short-term safety of bronchial thermoplasty treatment in patients 
with moderate to severe asthma is based on the results of three randomized controlled trials 
[28,31,32]. Two trials compared bronchial thermoplasty with usual care, the Asthma 
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[30]Intervention Research (AIR) trial [31] and the Research in Severe Asthma (RISA) trial [32], 




In the AIR trial, bronchial thermoplasty reduced the rate of mild exacerbations and improved 
asthma quality of life questionnaire (AQLQ) scores compared to the usual care group at 12 
months [31]. The RISA trial [32], which was primarily designed as a safety study, recruited 34 
patients with severe asthma of whom half were taking maintenance oral prednisolone daily, 
reported that bronchial thermoplasty improved AQLQ scores, asthma control questionnaire 
(ACQ) scores and rescue medication use compared to usual care at 12 months [32]. There was a 
trend for more patients in the bronchial thermoplasty group to wean off oral corticosteroids. 
The pivotal AIR2 trial, which compared bronchial thermoplasty with a sham procedure in 288 
adults with moderate to severe asthma, reported that bronchial thermoplasty improved AQLQ 
scores compared with the sham group (change in AQLQ with bronchial thermoplasty, 1.35 
versus 1.16 with sham) [28] (Figure 1). A larger proportion of patients in the bronchial 
thermoplasty group (79%) compared with the sham group (64%) achieved changes in AQLQ of 
0.5 or greater in the period from 6 to 12 months after the treatment period [28]. In the post-
treatment period (end of treatment period to one year), bronchial thermoplasty compared with 
the sham procedure reduced the number of severe exacerbations per subject per year by 32% 
(0.48 (0.067) bronchial thermoplasty vs 0.70 (0.122) sham] and emergency department visits by 
84% (0.07 bronchial thermoplasty vs. 0.43 sham visits/subject/year) (Figure 1). Bronchial 
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thermoplasty produced no consistent improvement in ACQ scores or FEV1 compared with the 
sham subjects [28]. Observational follow-up data beyond one year of patients who completed 
the AIR2 trial, but not including the sham group, reported that the reduction in the proportion 
of subjects experiencing severe exacerbations and emergency department visits after bronchial 
thermoplasty was maintained up to 5 years [33] (Figure 2). An exploratory analysis of the AIR2 
results found that a clinically significant improvement in AQLQ score (>0.5) at 1 year in patients 
treated with bronchial thermoplasty was associated with fewer severe exacerbations and 
emergency department visits over 5 years compared to those who did not experience clinically 
significant AQLQ response at year 1 [34]. A Cochrane systematic review of the three 
randomized controlled trials of bronchial thermoplasty concluded there was a modest clinical 
benefit in quality of life (mean difference in AQLQ score 0.28, 95% confidence interval (CI) 0.07 
to 0.50) and a significant reduction in severe exacerbation rates 12 months after treatment, 
based on the results of the AIR2 trial [17]. Potential weaknesses in the strength of the evidence 
from the AIR2 trial have been highlighted, including the proportion of patients recruited to the 
trial who had severe refractory asthma, whether changes in the primary end point AQLQ were 
statistically and clinically significant  and  whether appropriate methods were used to analysis 
some of the secondary end points [35]. Castro and several other coauthors of the AIR2 trial 
have provided a rebuttal of the criticisms [36]. In summary, randomized controlled clinical trials 
of bronchial thermoplasty in patients with moderate and severe asthma show modest 
improvements in asthma quality of life and reductions in severe exacerbations and emergency 





Short-term safety  
 
Bronchial thermoplasty is associated with short-term increases in asthma-related symptoms 
and hospital admissions for asthma during the treatment period [28,31,32,37]. The main 
adverse effects are wheeze, cough, night awakening and discolored sputum, with most 
adverse events occurring in the first day after bronchoscopy and resolving within one week. In 
the AIR2 study, more hospital admissions occurred in the bronchial thermoplasty group 
(8.4%) compared with subjects in the sham group (2%) during the treatment phase [28]. Over 
the entire study period (from the day of first bronchoscopy to the 12-month follow-up) there 
was no difference in the number of respiratory-related hospital admissions per subject in the 
bronchial thermoplasty group (0.13, 10.5% of subjects) compared with the sham group (0.14 
(5.1% of subjects) [28]. A Cochrane systematic review of the three controlled trial of bronchial 
thermoplasty reported a 3.5 fold (95% CI 1.26 to 9.68) greater risk of hospitalization for 
respiratory adverse events during the treatment period [17]. During the post-treatment 
period there was no significant difference in the risk of hospital admission (risk ratio 1.12 




Observational data on the long-term safety of bronchial thermoplasty is available from the AIR, 
RISA and AIR2 trials up to five years post bronchial thermoplasty treatment [33,38,39]. 
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Respiratory adverse events, lung function and  rates of hospital admissions or emergency 
department are unchanged in years two to five following the AIR [38], RISA [39] and AIR2 trials 
(figure 2) [33]. Serial computed tomography (CT) scans performed in 97 (57%) of AIR2 subjects 
treated with bronchial thermoplasty who were followed up to five years showed no clinically 
significant structural abnormalities to the airways, except for three subjects who had increased 
or new bronchiectasis compared with the baseline [33]. A criticism of the long-term studies is 
that only the participants treated with bronchial thermoplasty were followed up after year one 
in the RISA and AIR2 trials and in the AIR trial, the usual care group were followed-up to the end 
of year three, whereas the bronchial thermoplasty group were followed for five years. The 
bronchial thermoplasty at 10 years follow-up or beyond (BT10+) observational study is 
underway to assess the safety and efficacy of the procedure in 196 patients who previously 
participated in the three clinical trials (ClinicalTrials.gov Identifier: NCT03243292) [30]. In 
summary, follow-up data beyond one year provides evidence for the long-term safety of the 
procedure up to five years in relation to respiratory adverse events reporting, stable lung 
function and lack of increase in hospital admissions and emergency department visits. 
 
3. Observational real-life studies in clinical practice 
 
The introduction of bronchial thermoplasty to clinical practice involves the treatment of real-
life patients with moderate and severe asthma, some of whom do not satisfy the inclusion and 
exclusion criteria used in the clinical trials (Table 1). Information on baseline characteristics and 
the effectiveness and safety of bronchial thermoplasty in clinical practice is available from 
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several case series originating from Australia, Brazil, Canada, France, Japan, Netherlands, 
United Kingdom and the United States [40-50] (Table 2) and from a United Kingdom national 
registry [51]. In 2017, the interim three-year results of the PAS2  (Post-FDA Approval Clinical 
Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma)  study were published, 
which is a prospective, open-label, multi-center observational post-market study mandated by 
the FDA to evaluate the durability of the treatment effect and the short and long-term efficacy 
and safety of the procedure [52]. The study enrolled 284 participants from 2011 at 27 centres in 
the United States (n=23) and Canada (n=4) of whom 279 patients received at least one 
bronchial thermoplasty treatment. The last patient is expected to complete five years of follow-




In general, patients treated with bronchial thermoplasty in clinical practice have more severe 
disease than those recruited to AIR [31] and AIR2 [28] trials (Table 2). In one case series that 
compared safety and efficacy outcomes 12-months post-procedure in ten clinic patients with 
fifteen patients recruited to clinical trials of bronchial thermoplasty at the same center found 
that asthma severity was greater in clinic patients compared to research patients with 6/10 
[60%) clinic patients at British guideline on the management of asthma Step 5 treatment, 
compared to 2/15 (13%) of the research patients. Baseline asthma control and number of 
exacerbation was worse in the clinic group [41]. Participants in the PAS2 study compared with 
those recruited to the AIR2 clinical trial were slightly older, had a higher proportion taking 
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maintenance oral corticosteroids (18.9% vs 4.2%) and had more subjects who experienced 
severe exacerbations (74% vs 52%) and hospitalizations (15.3% vs 4.2%) in the 12 months prior 
to bronchial thermoplasty. In addition, more subjects in  the PAS2 study had chronic sinus 
disease (30.4% vs 18.4%) and a larger number had severe asthma (94.7% vs 82.1%)[52]. The 
British Thoracic Society (BTS) Difficult Asthma Registry and Hospital Episodes Statistics database 
of 59 patient with severe refractory asthma undergoing bronchial thermoplasty in clinical 
practice in the UK between 2011 and 2015 reported that bronchial thermoplasty patients were 
on average, older, had worse baseline FEV1 and lower AQLQ scores compared with published 
clinical trials [51].  
 
Effectiveness and safety 
 
Despite the limitations of an observational study design, the interim-analysis of PAS2 study 
suggests that improvements in efficacy outcomes in the PAS2 populations and AIR2 participants 
were similar [52]. At three years post-treatment, the proportion of people with severe 
exacerbations, emergency department visits and hospitalizations was reduced by 45%, 55%, 
and 40% respectively when compared to the 12 months prior to treatment, which were 
comparable to reductions of 37%, 72% and 25% respectively reported in AIR2 [28]. Pre- and 
post-bronchodilator spirometry was unchanged over the 3 years of follow-up after bronchial 
thermoplasty. Previous published information from observational studies on the effectiveness 
of bronchial thermoplasty for severe asthma in real-life patients have reported improvement in 
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AQLQ scores, reductions in exacerbations and/or a step-down in treatment in 50% to 75% of 
patients undergoing the procedure (Table 2).  
 
Respiratory-related serious adverse effects during the treatment phase with bronchial 
thermoplasty (first bronchial thermoplasty treatment to 6 weeks after last procedure) were 
greater in the PAS2 study [52] compared to the AIR2 [28] for severe exacerbations (55.8% vs. 
40.5% respectively) and emergency room visits (15.8% vs. 5.3% respectively), whereas 
emergency respiratory hospital readmission rates (within 30 days) of bronchial thermoplasty 
were similar (13.2% vs 8.4% respectively). Previous observational studies report hospital 
admissions ranging from 10% [45] to 30% [41] during the treatment phase. The BTS Difficult 
Asthma Registry recorded a hospital admission rate of 11.8% in 59 cases undergoing bronchial 
thermoplasty in the United Kingdom [51]. Patients have been reported to safely undergo 
bronchial thermoplasty with baseline characteristics that would have excluded them from 
enrolment to the AIR2 trial including those with prebronchodilator FEV1 < 60% predicted 
[40,48] and who were former smokers with more than 10 pack years total smoking history [42].  
 
CT imaging performed the day after bronchial thermoplasty in 13 patients with severe asthma 
demonstrated pulmonary peribronchial consolidations and ground-glass opacities in all treated 
lobes and mild involvement of an adjacent untreated lobe in 32% of cases [53]. The CT changes 
were not associated with respiratory symptoms and deceased or disappeared without 
treatment after one month. Another study of 12 patients with severe asthma found CT changes 
shortly after bronchial thermoplasty that included peribronchial consolidations with 
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surrounding ground glass opacities (94%), atelectasis (38%), partial bronchial occlusions (63%), 
and bronchial dilatations (19%) [54]. Follow-up CT scans at 6 months showed resolution of the 
changes except for an area of focal bronchiectasis in a single airway. In summary, these studies 
indicate that bronchial thermoplasty-induced acute CT pulmonary peribronchial consolidation 
frequently occurs and that these changes resolve in most patients within one to six months. 
 
The strength of the evidence provided from observational studies on the effectiveness and 
safety of bronchial thermoplasty in real-life patients has several weaknesses including the lack 
of control groups that was not treated with bronchial thermoplasty and it is unclear whether 
improvements in clinical outcomes differ from usual care [55].  The PAS2 study population is 
described as real-world, although the most severe patients seen in clinical practice were 
excluded, such as those with a baseline forced expiratory volume in 1 second (FEV1) <60%, 
more than 3 hospitalizations, 4 or more courses of systemic corticosteroids in the last 12 
months and oral corticosteroids maintenance dose >10 mg daily (Table 1). 
 
In summary, real-life patients treated with bronchial thermoplasty in clinical practice tend to 
have more severe disease than those treated in clinical trials of the procedure. The interim-
analysis of PAS2 suggests that reductions in exacerbations rates and emergency department 
visits at 3-year post bronchial thermoplasty in patients with severe asthma are comparable to 
those reported in the AIR2 trial, although adverse respiratory effects occur more frequently 
during the treatment period.  Observational studies report that bronchial thermoplasty is 
effective in one half to three-quarters of real-life patients with severe asthma. The procedure 
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can be safely performed in clinical practice although peri-procedure adverse effects are 
commoner than reported in clinical trials of bronchial thermoplasty. 
 
4. Important unresolved issues about bronchial thermoplasty 
 
Unresolved issues about bronchial thermoplasty include uncertainties about its place in the 
management of severe asthma, predictors of a beneficial response and mechanism(s) of action. 
 
Place of bronchial thermoplasty in the management of severe asthma 
 
The Global Initiative for Asthma (GINA) guideline for adults and adolescents with asthma 
recommends a step-wise approach to control symptoms and minimize future risk and to reduce 
treatment burden, especially from oral corticosteroid use in patients with severe disease [1]. 
Patients with severe asthma (step 5) who have persistent symptoms and exacerbations should 
be assessed by a specialist in severe asthma to confirm the correct diagnosis and to address 
aggravating factors, such as non-adherence, poor inhaler technique and co-morbidities. Add-on 
treatment options for patients with uncontrolled asthma despite receiving high dose ICS plus 
LABA and the antimuscarinic agonist tiotropium include biologics, such as anti-IgE therapy and 
anti-IL-5 therapy and low dose oral corticosteroid. Precision medicine is increasingly being used 
in the management of severe asthma due to the availability of biomarkers that can predict a 
positive response to specific interventions. For example, elevated total serum IgE levels, as well 
as biomarkers of type 2 inflammation [56], help select patients with severe allergic asthma 
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suitable for anti-IgE therapy with omalizumab and a raised blood eosinophil count identifies 
patients suitable for therapy with monoclonal antibodies targeting IL-5 with subcutaneous 
mepolizumab [57], intravenous reslizumab [58] or subcutaneous benralizumab [59]. The GINA 
guideline considers bronchial thermoplasty as a potential treatment option at step 5 in some 
countries for selected adults with severe asthma whose asthma remains uncontrolled despite 
optimized therapy and review by an asthma specialist [1]. Evidence is considered limited 
(Evidence B) and long-term effects compared to controls are not known. Longer-term safety 
follow-up of larger number of active and control patients is required to assess effectiveness and 
safety [1]. The International ERS/ATS Guidelines on Definition, Evaluation and Treatment of 
Severe  Asthma  recommend that bronchial thermoplasty is performed in adults with severe 
asthma only in the context of an Institutional Review Board approved independent systematic 
registry or a clinical study [5]. The British guideline on the management of asthma recommends 
that bronchial thermoplasty is a modestly effective treatment option for selected patients with 
moderate to severe asthma who have poorly controlled asthma despite maximal therapy [60].  
 
Patients selected for bronchial thermoplasty in clinical practice are more likely to have clinical 
features of more severe disease than those recruited to clinical trials of the procedure.  Several 
authors have suggested that bronchial thermoplasty should be considered for patients with 
severe asthma associated with non-type 2 inflammation and non-eosinophilic inflammation 
[61,62]. To date, there are no clinical trials that that have directly compared the effectiveness 
of bronchial thermoplasty in severe asthma with biological agents, such as omalizumab or anti-
IL-5 therapies. Possible biomarkers that predict a favourable response to bronchial 
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thermoplasty are being assessed and are reviewed in the next section. The balance of risks and 
benefits of bronchial thermoplasty treatment should be discussed with patients. Patients with a 
pacemaker, internal defibrillator, or other implantable electronic device, known sensitivity to 
medications required to perform bronchoscopy or who have previously received treatment 
with bronchial thermoplasty should not receive bronchial thermoplasty treatment.  
 
Several studies have estimated the cost-effectiveness of bronchial thermoplasty compared to 
usual care in patients with severe asthma treated in different health care systems. In the United 
States, bronchial thermoplasty is estimated to be cost-effective in patients with severe 
uncontrolled asthma who have a high risk of exacerbations [63] or in patients with moderate to 
severe allergic asthma [64], whereas in Singapore, the procedure is not cost-effective compared 
to optimized usual care [65]. The likelihood of bronchial thermoplasty being a cost-effective 
treatment for severe asthma in a health care system are greater if the costs of hospitalization 
and emergency department are high and the costs of the procedure are low [65]. Other factors 
that influence the cost-effectiveness of bronchial thermoplasty are a patient’s risk of a future 
exacerbation, the duration of follow-up after treatment and the health systems threshold in 
dollars for the willingness-to-pay per quality-adjusted life years (QALY). An indirect comparison 
of bronchial thermoplasty with omalizumab suggested that there was more than a 60% chance 
that bronchial thermoplasty became cost-effective relative to omalizumab and standard 
therapy at the willingness-to-pay of $100,000 per QALY in patients with moderate-to-severe 
allergic asthma in the United States [64,66]. Another study, using data from the AIR2 trial of 
bronchial thermoplasty and two placebo-controlled trials of omalizumab (INNOVATE [67] and 
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EXTRA [68]), reported broadly similar clinical outcomes with the two treatments, including 
severe exacerbations, emergency department visits, and hospital admissions [66]. Asthma-
related emergency department visits were less for the post-treatment period of the AIR2 trial 
compared to omalizumab and severe exacerbations were less for omalizumab compared to the 
total duration of the AIR2 study that included the increase in exacerbations during the per-
treatment period [66]. Future studies should assess the cost effectiveness of bronchial 
thermoplasty with the long-term use of biologics or maintenance oral corticosteroids. 
 
In summary, bronchial thermoplasty is a treatment option for selected patients with moderate 
to severe asthma who have poorly controlled asthma despite maximal therapy. There is a lack 
of evidence about which subphenotype(s) of severe asthma should be treated with bronchial 
thermoplasty compared to other treatments, such as biological agents. Some experts have 
recommended that bronchial thermoplasty should be used mainly in patients with severe 
asthma associated with non-type 2 inflammation and non-eosinophilic inflammation or as a 
second-line alternative therapy for patient unresponsive to currently licenced biologics. 
 
Predicting a beneficial response to bronchial thermoplasty  
 
There is limited information on factors that can identify patients with severe asthma who will 
obtain clinical benefits from bronchial thermoplasty, particularly alongside the use of new 
biologic therapies. Clinical and physiological variables, such as a history of allergy [33] or 
bronchodilator reversibility [45] are not predictive. Preliminary  findings from a United States 
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study of 47 patients with severe asthma suggested that patients with early onset atopic severe 
asthma tend to respond better than other phenotypes to bronchial thermoplasty [49]. Another 
preliminary report suggested that shorter duration of asthma, lower baseline AQLQ score and 
higher continuous maintenance oral corticosteroid dose may be predictive [69] although 
further confirmatory evidence is awaited. Future analysis of the large PAS2 population of severe 
asthma may identify potential clinical predictors of response [52].   
 
Using data from 24 consecutive cases of severe asthma treated with bronchial thermoplasty at 
three Australian centres, Langton and colleagues [70] found that the number of activations 
delivered to the airways was lower in non-responders compared to responders (139 ± 11 
activations versus 221 ± 45 activations respectively) and the improvement in ACQ score 
correlated with a greater number of activations. In another study, the cumulative number of 
activations administered during three sessions of bronchial thermoplasty were not associated 
with bronchial biopsy histological changes induced by the procedure [44]. 
 
Biomarkers of airway inflammation, such as sputum differential cell count and exhaled nitric 
oxide were not measured in the clinical trials of bronchial thermoplasty and to date it is 
unknown whether these variables are predictive of a beneficial response to bronchial 
thermoplasty. One preliminary report found that responders to bronchial thermoplasty had 
lower serum periostin levels and exhaled nitic oxide (FeNO) levels compared to non-responders 
[71]. To date, preliminary findings from bronchial biopsy studies of patients undergoing 
bronchial thermoplasty have found that the amount of airway smooth muscle at baseline does 
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not predict a beneficial response [44,50] (ClinicalTrials.gov Identifier: NCT01777360; 
NCT02225392) [30]. Imaging of the airways by optical coherence tomography [72], CT [47] and 
endobronchial ultrasound are potential methods to identify predictors of response to bronchial 
thermoplasty. Optical coherence tomography of the airway performed 2-years after  bronchial 
thermoplasty in two patients  reported a decrease in airway wall thickness in one patient who 
responded to the procedure and an increase in the other demonstrated differences in airway 
wall features between the responder and non-responder prior to treatment [72]. The BTR 
(Biopredictors of Bronchial Thermoplasty Response in Patients With Severe Refractory Asthma) 
study is underway to determine whether baseline clinical, physiologic, biologic and imaging 
markers can identify those patients with severe asthma who will obtain greatest benefit from 
bronchial thermoplasty (ClinicalTrials.gov Identifier: NCT01185275) [30]. 
 
Mechanism of action of bronchial thermoplasty 
 
Several mechanisms of action of bronchial thermoplasty have been proposed, including 
alterations to the structure or function of airway smooth muscle and/or other airway cells and 
structures including epithelial cells, nerves, extracellular matrix and inflammatory cells [73].  
 
Reduced airway smooth muscle mass 
 
Increased airway smooth muscle mass in asthma [74], particularly in severe disease [75],  may 
contribute to impaired lung function, airway hyperresponsiveness and poor symptom control 
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[76,77]. Bronchial thermoplasty reduces the amount of airway smooth muscle in experimental 
animals [22] and in patients with bronchial carcinoma awaiting lung resection [25].  Bronchial 
biopsy studies in asthma have confirmed that airway smooth muscle mass is reduced by 
bronchial thermoplasty (Figure 3) [42-44,78,79]. Preliminary findings from the TASMA 
(Unravelling Targets of Therapy in Bronchial Thermoplasty in Severe Asthma) study , in which 
patients were randomized to either bronchial thermoplasty or delayed treatment after six 
months, reported that airway smooth muscle mass decreased after bronchial thermoplasty, but 
did not change in the controls or the untreated right middle lobe  (ClinicalTrials.gov Identifier: 
NCT02225392) [30,80].  Several studies have investigated whether structural changes to the 
airway are associated with improvements in clinical outcomes. In the ASMATHERM (Bicentric 
Prospective Study, Evaluating Bronchial THERMOPLASTY in Patients Presenting Severe 
Uncontrolled Asthma) study of 15 patients with severe asthma, Pretolani and colleagues [44] 
found that the reduction in airway smooth muscle mass correlated with the improvement in 
asthma control and quality of life and decrease in severe exacerbations at 1 year after bronchial 
thermoplasty (ClinicalTrials.gov Identifier: NCT01777360) [30]. Another study found no 
association between reduction in airway smooth muscle mass or reticular basement membrane 
thickness and clinical improvements after bronchial thermoplasty [42,43]. Imaging techniques 
have been used to investigate the effects of bronchial thermoplasty on airway thickness. A 
study of 26 patients with severe asthma showed improvements in CT airway wall thickness and 
air trapping one year after bronchial thermoplasty [47]. Another study using three-dimensional 
airway analysis of CT scans performed before and after bronchial thermoplasty in one patient 
demonstrated dilation of the bronchial lumen and decreased bronchial wall thickness [81]. 
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Optical coherence tomography of the airway performed 2-yeasr after  bronchial thermoplasty 
in two patients  reported a decrease in airway wall thickness in a patient who responded to the 
procedure and an increase in the non-responder [72]. In summary, these findings suggest that 
bronchial thermoplasty is likely to decrease airway smooth muscle mass in asthma, but they do 
not establish whether the clinical benefits are due to this mechanism.   
 
Altered airway smooth muscle function 
 
Bronchial thermoplasty could alter airway function by reducing contractility of airway smooth 
muscle [82]. The contraction of bovine airway smooth muscle to acetylcholine is inhibited at 
temperatures greater than 55°C and actin-myosin interactions are similarly temperature 
sensitive.  Whether the acute effect of temperatures in vitro smooth muscle responsiveness 
translates to long-term reductions in airway contractility after bronchial thermoplasty is 
unclear. Bronchial thermoplasty may also alter airway function by stiffening the airway wall [22] 
or by reducing the secretion of pro-inflammatory mediators from airway smooth muscle cells 
[77].  
 
Altered airway epithelial cells, glands, nerves, extracellular matrix components 
 
Bronchial thermoplasty might improve clinical outcomes in asthma by altering the structure 
and/or function of airway epithelial cells, glands, nerves or extracellular matrix components. In 
one observational study, bronchial thermoplasty reduced subepithelial basement membrane 
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thickening, submucosal nerves, airway smooth muscle-associated nerves and epithelial 
neuroendocrine cells (Figure 3) [44]. No effect was found on subepithelial mucous glands or the 
epithelial structure, including the proportion of regenerating bronchial epithelium or normal 
stratified columnar, metaplastic, or squamous epithelium or goblet cell hypertrophy or 
hyperplasia at one year after the procedure [44]. In another study, bronchial thermoplasty 
decreased type I collagen deposition and reticular basement membrane  thickness [42,43]. A 
preliminary report from this latter study found that the bronchial epithelium showed increased 
cell proliferation and basal progenitor cells numbers and reduced MUC5AC mucin expression 
[83] that correlated with the reduction in the rates of severe exacerbations during the ≥27-
month post-bronchial thermoplasty period [83]. The authors speculate that the long-term 
benefits from bronchial thermoplasty may be due, at least in part, to an improvement in the 
structure of the bronchial epithelium [83]. Another preliminary study reported increased 
epithelial integrity six months following bronchial thermoplasty [84]. In a study of 15 patients 
with severe asthma, Pretonali and colleagues [44] found that the reduction in submucosal 
nerves and number of epithelial neuroendocrine cells correlated with the decrease in severe 
exacerbations at 1 year after bronchial thermoplasty. The reduction in the number of epithelial 
neuroendocrine cells also correlated with improvement in asthma control test (ACT) and AQLQ 
scores [44]. In summary, preliminary data suggests that airway epithelium and nerves may be 






Information is limited about the effects of bronchial thermoplasty on biomarkers of 
inflammation in asthma. A recent study in 11 patients with severe asthma reported a decrease 
in bronchoalveolar lavage concentrations of transforming growth factor β1 and chemokine (C-C 
motif) ligand 5 (CCL5) at 6 weeks after bronchial thermoplasty whereas IL-4, IL-5, and IL-17 
levels were unaffected [79]. A small retrospective uncontrolled study of 15 patients undergoing 
bronchial thermoplasty reported a reduction in peripheral blood eosinophil count at one year 
after the procedure, although the mechanism is uncertain [85]. Bronchial mucosal eosinophils 
are not reduced after bronchial thermoplasty, suggesting that the clinical benefits of bronchial 
thermoplasty are not due to attenuated airway eosinophilic inflammation [44]. A preliminary 
report on the effects of bronchial thermoplasty on blood gene expression found that multiple 
pathways decrease significantly including pathways associated with eosinophilic inflammation, 
T cell activation, and neuronal function [86]. The authors speculate that the beneficial effects of 
bronchial thermoplasty may be in part due to modulation of allergic inflammation and neuronal 
control of airway function [86] 
 
Site of action in the airways 
 
Small airway dysfunction is a feature of severe asthma [87]. It is uncertain whether bronchial 
thermoplasty influences the structure or function of peripheral airways (<3 mm), particularly as 
treatment is applied to large airways (>3 mm). CT imaging performed shortly after bronchial 
thermoplasty shows acute peribronchial consolidations adjacent to treated airways that is likely 
to involve the peripheral airways [53,54]. Preliminary findings from small observational studies 
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in patients with severe asthma pre- and post-bronchial thermoplasty found improvements in 
measurements of small airway dysfunction assessed by the forced oscillatory technique and by 
measurement of static and dynamic lung compliance and lung resistance [88,89]. Taken 
together, this recent preliminary data suggests that some of the clinical benefits of bronchial 




Sham interventions are associated with considerable placebo effects  in medical device trials 
[91]. In the AIR2 trial, the sham-controlled  arm was associated with increased AQLQ scores, 
although the bronchial thermoplasty produced greater improvements in AQLQ scores, and was 
associated with a reduction in severe exacerbations and emergency room visits [28]. Some of 
the clinical benefits from bronchial thermoplasty in asthma may be due to a placebo effect. 
 
5. Expert commentary 
 
Severe refractory asthma, although uncommon, causes considerable morbidity and mortality 
and generates high health care costs. Until recently, there were limited advances in the 
therapies available for severe asthma. The recognition of the heterogeneity of clinical and 
inflammatory phenotypes of severe asthma has resulted in the development and licencing of 
new biological therapies targeting specific immunological pathways [1]. Bronchial thermoplasty, 
which involves the delivery of radio frequency energy to the airways, is a non-pharmacological 
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intervention developed for the treatment of severe asthma, which has been approved for use 
in many countries world-wide. The main evidence for the effectiveness of bronchial 
thermoplasty for the treatment of severe asthma is based on the results of three randomized 
controlled trials, only one of which compared the procedure with a sham control (AIR2) [28]. 
The methods of analysis and interpretation of the results of these trials has generated 
considerable debate and the lack of inclusion of the sham-control group or usual care groups in 
the long-term follow-up safety studies has been criticised. Biologics and small-molecule drugs 
for asthma require evidence of efficacy and safety in replicate phase 3 clinical trials before 
being considered for regulatory approval, whereas a medical device, such as that used to 
administer bronchial thermoplasty required less stringent criteria of efficacy for approval. A 
replicate of the AIR2 trial would have been helpful in assessing the effectiveness of bronchial 
thermoplasty. Despite the weaknesses in the evidence for the efficacy and safety of bronchial 
thermoplasty from clinical trials, overall, these studies shown that bronchial thermoplasty 
produces modest improvements in asthma quality of life and reductions in the frequency of 
severe exacerbations. During the treatment period, bronchial thermoplasty is associated with 
increased asthma-related symptoms and hospital admissions for asthma. Long-term follow-up 
studies have not reported any serious adverse effects. 
 
The introduction of bronchial thermoplasty to clinical practice has resulted in its use in real-life 
patients, some of whom do not satisfy the inclusion and exclusion criteria for the clinical trials. 
Observational studies indicate that real-life patients are more likely to have clinical features of 
severe disease than AIR2 participants. The efficacy and safety of bronchial thermoplasty in real-
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life studies is comparable to AIR2, although a major weakness of the data is the lack of a control 
group that was not treated with bronchial thermoplasty. The PAS2 observational study, which 
provides the largest data on real-life patients undergoing bronchial thermoplasty, offers 
reassurance on the long-term safety of bronchial thermoplasty in clinical practice, although the 
interim results await confirmation when the PAS2 cohort reach 5-years of follow-up in 2020. It 
is important that the short-term and long-term effectiveness and safety of bronchial 
thermoplasty in real-world populations continues to be recorded in national [51] and 
international databases (ClinicalTrials.gov Identifier: NCT02104856) [30].  
 
The place of bronchial thermoplasty in the management of severe asthma is uncertain. Several 
subtypes or phenotypes of severe asthma are recognized, based on clinical, physiological or 
immunological variables, and these are used to classify asthma and to predict response to 
therapy [12,13]. Type 2 inflammation is closely associated with eosinophilic inflammation and 
predicts a favourable therapeutic response to biological agents targeting the Th2 pathway 
including interleukin (IL)s 4, IL-5, IL-13 and anti-thymic stromal lymphopoietin (TLSP). Non-
eosinophilic inflammation and non-type 2 inflammation are poorly responsive to current 
therapies including corticosteroids [12,92]. An algorithm for the use of bronchial thermoplasty 
and biologics in management of severe asthma in clinical practice is outlined in Figure 4. 
Currently, the suggestion that bronchial thermoplasty should be considered for patients with 
severe asthma associated with non-type 2 inflammation and non-eosinophilic inflammation is 
based on the availability of effective biologics therapies for type 2 inflammation and 
eosinophilic inflammation, rather than because of evidence that the efficacy of bronchial 
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thermoplasty is related to specific inflammatory phenotypes of severe asthma. Clinical trials 
that directly compared bronchial thermoplasty, biologics such as omalizumab, anti-IL-5 
monoclonal antibodies  and novel small molecule drugs [93] in severe asthma could help 
establish validated treatment pathways. 
 
Potential clinical or inflammatory biomarkers that might predict a beneficial response to 
bronchial thermoplasty, such as early age of onset of asthma, non-type 2 inflammation, 
increased airway smooth muscle mass or CT or optical coherence tomography images and 
number of activations delivered to the airways need to be validated in large populations of 
patients with severe asthma. Studies underway may provide insights into predictors of 
response to bronchial thermoplasty [30]. Possible modes of action of bronchial thermoplasty 
under investigation include reduced airway smooth muscle mass or function, alterations to the 
structure and/or function of airway epithelial cells, nerves or extracellular matrix components. 
Studies are underway to investigate the mode of action of bronchial thermoplasty and to 
identify biomarkers that predict a beneficial response [30].  
 
6. Five-year review 
 
The strict eligibility criteria used in many clinical trials of therapies for severe asthma exclude 
over 90% of real-life patients [94] suggesting that guideline recommendations may not be 
applicable to all patients with severe asthma seen in daily practice. Ideally, new clinical trials 
will provide data on the effectiveness of bronchial thermoplasty treatment for severe asthma, 
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particularly in high-risk patients, compared to a sham procedure or to new biologics. 
Unfortunately, new large clinical trials may not be undertaken due to their high costs and 
potential difficulties undertaking comparative clinical studies using treatments developed by 
different pharmaceutical and device companies. Over the next five years, new data on the 
effectiveness and safety of bronchial thermoplasty and the identification of predictors of 
response is likely to come from observational studies in real-world populations of severe 
asthma.  Greater understanding of the sub-phenotypes of severe asthma and mode of action of 
bronchial thermoplasty may aid the introduction of a precision medicine approach to the use of 
bronchial thermoplasty in the management of severe asthma. Alternative approaches to target 
airway smooth muscle may be developed for clinical use, such by electroporation ablation of 





Key issues  
 
 Bronchial thermoplasty is an intervention developed for the treatment of patients with 
severe asthma, which involves the delivery of radio frequency energy to the airways. 
 Randomized controlled clinical trials of bronchial thermoplasty in patients with moderate 
and severe asthma show modest improvements in asthma quality of life and reductions in 
severe exacerbations and emergency department visits.  
 Morbidity from asthma is increased during treatment. Follow-up data beyond one year have 
not reported any serious adverse effects up to five years  
 Observational studies report that bronchial thermoplasty is effective in one half to three-
quarters of real-life patients with severe asthma. The procedure can be safely performed in 
clinical practice although per-procedure adverse effects are commoner than reported in 
clinical trials of bronchial thermoplasty. 
 Bronchial thermoplasty is a treatment option for selected patients with moderate to severe 
asthma who have poorly controlled asthma despite maximal therapy. It is not known which 
subphenotype(s) of severe asthma should be treated with bronchial thermoplasty 
compared to other treatments, such as biological agents. Currently, bronchial thermoplasty 
is mainly used in patients with severe asthma associated with non-type 2 inflammation and 
non-eosinophilic inflammation or as a second-line alternative therapy for patient 
unresponsive to currently licenced biologics. 
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 Preliminary data suggest that certain clinical variables or inflammatory biomarkers might 
predict a beneficial response to bronchial thermoplasty, but these factors need to be 
validated in large populations of patients with severe asthma. 
 Modes of action of bronchial thermoplasty under investigation include reduced airway 
smooth muscle mass or function, alterations to the structure and/or function of airway 
epithelial cells, nerves or extracellular matrix components. 
 Future research needs to investigate uncertainties about predictors of response, 
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TABLE 1:  Key exclusion criteria used in the AIR, RISA or AIR2 trials of bronchial thermoplasty 
in asthma [28,31,32]* 
 
 Aged >65 years 
 Chronic sinus disease  
 Prebronchodilator FEV1 <60% predicted (AIR and AIR2); FEV1 < 50% predicted (RISA trial) 
 Four or more oral corticosteroid courses for asthma exacerbation within the past 12 months 
 Three or more hospitalisations for asthma within the past 12 months 
 Former smoker, if more than 10 pack years total smoking history  
 A history of intubation for asthma, or ICU admission for asthma within the prior 24 months 
 Taking maintenance oral corticosteroids >10 mg daily (AIR2 trial) or > 30 mg daily (RISA trial). 
 
Footnote 
* Note: Similar key exclusion criteria were used in the PAS2 study [52] and AIR2 trial, except for 




Table 2: Observational studies of baseline characteristics, efficacy and safety outcomes in real-life patients with severe asthma treated with 
bronchial thermoplasty † 























Number 10 16 15 20 12 26 190 147 47 11 
Maintenance oral corticosteroids 
(%) 














thermoplasty when clinical 
outcomes assessed, months 
12 12 [42] 
(n=9, 
>27)[43] 
12 6 12 12 36 12 12 6 








NR NR NR NR Improved  
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NR NR NR Improved 
Severe exacerbations Decreased 
(30%)* 
Decreased Decreased Decreased Decreased 
(83%) 




ED visits or hospital admissions Decreased 
(30%)* 
NR Decreased NR Decreased NR Decreased Decreased Decreased NR 




Decreased Decreased Decreased 
(n=1) 
NR Decreased Decreased NR NR 






Increased  No change No change No change No change NR 
Assessment of overall beneficial 
response to bronchial 
thermoplasty during the post-
treatment period (percent) 
50% NR 73% 65-85% >80% 65% NR NR NR 55% 
Number of hospital admissions 
due to asthma during to the peri-





NR 2 (1 patient) NR NR 13.2% 21% NR NR 
 47 
† Observational studies reporting results of bronchial thermoplasty from 10 or more patients with severe asthma.  
†† Preliminary reports published as abstracts. 
 
Abbreviations: FEV1, forced expiratory volume in one second; ED, emergency department; NR, not reported; PAS2, Post-FDA 
Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma 
#  Assess using different asthma symptom questionnaire: asthma control questionnaire[41,45,50]; asthma control test [44]; asthma 
control scoring system [42,43] 








Title: (A) Total Asthma Quality of Life Questionnaire (AQLQ) score over 12 months after 
treatment with bronchial thermoplasty and (B) healthcare utilization events during the 
post-treatment period. 
 (a) Change in Asthma Quality of Life Questionnaire (AQLQ) score over 12 months after 
treatment with bronchial thermoplasty (BT) (diamonds) or sham control (squares) in the per 
protocol population. *Posterior probability of superiority = 97.9%.   
(b) Severe exacerbations (exacerbation requiring treatment with systemic corticosteroids or 
doubling of the inhaled corticosteroids dose), emergency department visits, and 
hospitalizations occurring in the post-treatment period. Open bars, sham; shaded bars, 
bronchial thermoplasty. All values are means ± SEM. *Posterior probability of superiority = 
95.5%. Posterior probability of superiority = 99.9%.’ 
Reprinted with permission of the American Thoracic Society. Copyright © 2017 American 
Thoracic Society. [28]. The American Journal of Respiratory and Critical Care Medicine is an 








Title: Severe exacerbations and Emergency Department visits in the 5 years after bronchial 
thermoplasty 
A, Proportion of subjects with severe exacerbations. B, Severe exacerbation rates. C, 
Proportion of subjects with emergency department (ED) visits for respiratory symptoms. D, 
ED visit rates. Values are point estimates with 95% upper and lower CIs. The 365-day period 
constituting year 1 began at 6 weeks after the last bronchial thermoplasty bronchoscopy.  




Title: Structural effects of bronchial thermoplasty in bronchial biopsy specimens from 
patients with severe asthma.  
 ‘Bright-field micrographs of bronchial biopsy specimens subjected to quadruple 
immunohistochemical staining for smooth muscle actin (red), the vascular endothelial marker 
CD31 (green), lymph endothelial marker, podoplanin (D2-40, brown), and the neuronal 
marker PGP.9.5 (black) are shown. A and B, Biopsy specimens taken before and 3 months 
after bronchial thermoplasty, respectively (note that Fig 2, B, rather than representing the 
average, exemplifies a case in which smooth muscle was virtually absent). C, A 
neuroendocrine cell (NEC) in the bronchial epithelium detected based on nuclear distribution 
of PGP (arrowhead). D and E, Subepithelial nerves (arrowheads) in the subepithelial region 
before (Fig 2, D) and after (Fig 2, E) bronchial thermoplasty. F, Smooth muscle–associated 
nerves (arrowhead) exemplified in a biopsy specimen collected before bronchial 
 50 
thermoplasty treatment. Scale bars 5 250 mm (Fig 2, A and B) or 40 mm (Fig 2, C-F). sm, 
Smooth muscle; bv, blood vessels; lv, lymphatic vessels’. 




Title: Algorithm to guide the selection of add-on treatment with biologics and bronchial 
thermoplasty for patients with severe refractory asthma*.  
* Patients with severe asthma (step 5) who have persistent symptoms and exacerbations 
should be assessed by a specialist in severe asthma to confirm the correct diagnosis and to 
address aggravating factors, such as non-adherence, poor inhaler technique and co-
morbidities. Add-on treatment with biologics and bronchial thermoplasty are considered for 
patients with uncontrolled asthma despite high dose ICS plus LABA and the long-acting 
muscarinic antagonist tiotropium.  
 
 
 
